Ignite Creation Date:
2024-05-06 @ 3:19 PM
Last Modification Date:
2024-10-26 @ 1:47 PM
Study NCT ID:
NCT04594135
Status:
UNKNOWN
Last Update Posted:
2021-03-02
First Post:
2020-10-14
Brief Title:
Anti-CD5 CAR T Cells for RelapsedRefractory T Cell Malignancies
Sponsor:
iCell Gene Therapeutics
Organization:
iCell Gene Therapeutics
Study Overview
Official Title:
Anti-CD5 CAR T Cells for RelapsedRefractory T Cell Malignancies
Status:
UNKNOWN
Status Verified Date:
2021-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CD5CAR-T
Brief Summary:
This is a phase I interventional single arm open label treatment study to evaluate the safety and tolerability of anti-CD5 CART cells in patients with relapsed andor refractory T cell lymphoma or leukemia
Detailed Description:
Anti- CAR is a chimeric antigen receptor immunotherapy treatment designed to treat lymphomaleukemia expressing CD5 antigen CD5 T cell lymphomas or leukemia are a subset of leukemias and lymphomas that are positive for the surface protein CD5 The purpose of this study is to evaluate the efficacy and safety of anti-CD5 CAR T cells
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None